Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer
Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., Slingerland, J., Silva, O., Welsh, C., Schuhwerk, K., Seo, P., Pegram, M. D., Glück, S.
Published in Breast cancer research and treatment (01.02.2012)
Published in Breast cancer research and treatment (01.02.2012)
Get full text
Journal Article
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
Blackwell, K. L., Pegram, M. D., Tan-Chiu, E., Schwartzberg, L. S., Arbushites, M. C., Maltzman, J. D., Forster, J. K., Rubin, S. D., Stein, S. H., Burstein, H. J.
Published in Annals of oncology (01.06.2009)
Published in Annals of oncology (01.06.2009)
Get full text
Journal Article
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.-J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J., Duffy, M.J.
Published in Annals of oncology (01.04.2006)
Published in Annals of oncology (01.04.2006)
Get full text
Journal Article
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
Pegram, Mark D., Pienkowski, Tadeusz, Northfelt, Donald W., Eiermann, Wolfgang, Patel, Ravi, Fumoleau, Pierre, Quan, Eleonor, Crown, John, Toppmeyer, Deborah, Smylie, Michael, Riva, Alessandro, Blitz, Sandra, Press, Michael F., Reese, David, Lindsay, Mary-Ann, Slamon, Dennis J.
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)
Get full text
Journal Article
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
Pietras, R J, Fendly, B M, Chazin, V R, Pegram, M D, Howell, S B, Slamon, D J
Published in Oncogene (01.07.1994)
Get more information
Published in Oncogene (01.07.1994)
Journal Article
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
PEGRAM, M. D, FINN, R. S, ARZOO, K, BERYT, M, PIETRAS, R. J, SLAMON, D. J
Published in Oncogene (31.07.1997)
Published in Oncogene (31.07.1997)
Get full text
Journal Article
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
AGUILAR, Z, AKITA, R. W, FINN, R. S, RAMOS, B. L, PEGRAM, M. D, KABBINAVAR, F. F, PIETRAS, R. J, PISACANE, P, SLIWKOWSKI, M. X, SLAMON, D. J
Published in Oncogene (28.10.1999)
Published in Oncogene (28.10.1999)
Get full text
Journal Article
Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5
Ward, T M, Iorns, E, Liu, X, Hoe, N, Kim, P, Singh, S, Dean, S, Jegg, A-M, Gallas, M, Rodriguez, C, Lippman, M, Landgraf, R, Pegram, M D
Published in Oncogene (09.05.2013)
Published in Oncogene (09.05.2013)
Get full text
Journal Article
Evolving HER2+ Metastatic Breast Cancer Landscape
Seidman, Andrew D, Bardia, Aditya, Pegram, Mark, Rao, Ruta
Published in Oncology (Williston Park, N.Y.) (01.12.2021)
Get full text
Published in Oncology (Williston Park, N.Y.) (01.12.2021)
Journal Article
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
Pegram, Mark D., Konecny, Gottfried E., O'Callaghan, Carminda, Beryt, Malgorzata, Pietras, Richard, Slamon, Dennis J.
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)
Published in JNCI : Journal of the National Cancer Institute (19.05.2004)
Get full text
Journal Article
HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer
Konecny, Gottfried E., Thomssen, Christoph, Lück, Hans Joachim, Untch, Michael, Wang, He-Jing, Kuhn, Walter, Eidtmann, Holger, Bois, Andreas du, Olbricht, Sigrid, Steinfeld, Dieter, Möbus, Volker, Minckwitz, Gunter von, Dandekar, Suganda, Ramos, Lillian, Pauletti, Giovanni, Pegram, Mark D., Jänicke, Fritz, Slamon, Dennis J.
Published in JNCI : Journal of the National Cancer Institute (04.08.2004)
Published in JNCI : Journal of the National Cancer Institute (04.08.2004)
Get full text
Journal Article
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
Pietras, R J, Arboleda, J, Reese, D M, Wongvipat, N, Pegram, M D, Ramos, L, Gorman, C M, Parker, M G, Sliwkowski, M X, Slamon, D J
Published in Oncogene (15.06.1995)
Get more information
Published in Oncogene (15.06.1995)
Journal Article
HER-2/neu as a predictive marker of response to breast cancer therapy
Pegram, M D, Pauletti, G, Slamon, D J
Published in Breast cancer research and treatment (01.01.1998)
Published in Breast cancer research and treatment (01.01.1998)
Get full text
Journal Article
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
Pegram, M D, Lipton, A, Hayes, D F, Weber, B L, Baselga, J M, Tripathy, D, Baly, D, Baughman, S A, Twaddell, T, Glaspy, J A, Slamon, D J
Published in Journal of clinical oncology (01.08.1998)
Published in Journal of clinical oncology (01.08.1998)
Get more information
Journal Article